Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1603-1609 |
| Number of pages | 7 |
| Journal | Dig. Liver Dis. |
| Volume | 53 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2021 |
Keywords
- Comorbidities
- Direct acting antivirals
- HCV Cohort
- Linked-to-care patients
Fingerprint
Dive into the research topics of 'Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort: Digestive and Liver Disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort : Digestive and Liver Disease. / Quaranta, M.G.; Ferrigno, L.; Tata, X. et al.
In: Dig. Liver Dis., Vol. 53, No. 12, 2021, p. 1603-1609.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort
T2 - Digestive and Liver Disease
AU - Quaranta, M.G.
AU - Ferrigno, L.
AU - Tata, X.
AU - D'Angelo, F.
AU - Massari, M.
AU - Coppola, C.
AU - Biliotti, E.
AU - Giorgini, A.
AU - Laccabue, D.
AU - Ciancio, A.
AU - Blanc, P.L.
AU - Margotti, M.
AU - Ieluzzi, D.
AU - Brunetto, M.R.
AU - Barbaro, F.
AU - Russo, F.P.
AU - Beretta, I.
AU - Morsica, G.
AU - Verucchi, G.
AU - Saracino, A.
AU - Galli, M.
AU - Kondili, L.A.
AU - Mazzaro, C.
AU - Bertola, M.
AU - Benedetti, A.
AU - Schiadà, L.
AU - Cucco, M.
AU - Giacometti, A.
AU - Brescini, L.
AU - Castelletti, S.
AU - Fiorentini, A.
AU - Angarano, G.
AU - Milella, M.
AU - Leo, A.D.
AU - Rendina, M.
AU - Salvatore D'ABRAMO, F.
AU - Lillo, C.
AU - Iannone, A.
AU - Piazzolla, M.
AU - Badia, L.
AU - Piscaglia, F.
AU - Benevento, F.
AU - Serio, I.
AU - Castelli, F.
AU - Zaltron, S.
AU - Spinetti, A.
AU - Odolini, S.
AU - Bruno, R.
AU - Mondelli, M.
AU - Chessa, L.
AU - Loi, M.
AU - Torti, C.
AU - Costa, C.
AU - Mazzitelli, M.
AU - Pisani, V.
AU - Scaglione, V.
AU - Trecarichi, E.M.
AU - Zignego, A.L.
AU - Monti, M.
AU - Madia, F.
AU - Attala, L.
AU - Pierotti, P.
AU - Salomoni, E.
AU - Mariabelli, E.
AU - Santantonio, T.A.
AU - Bruno, S.R.
AU - Cela, E.M.
AU - Bassetti, M.
AU - Mazzarello, G.
AU - Alessandrini, A.I.
AU - Biagio, A.D.
AU - Nicolini, L.A.
AU - Raimondo, G.
AU - Filomia, R.
AU - Aghemo, A.
AU - Meli, R.
AU - Lazzarin, A.
AU - Salpietro, S.
AU - Fracanzani, A.L.
AU - Fatta, E.
AU - Lombardi, R.
AU - Lampertico, P.
AU - Borghi, M.
AU - D'ambrosio, R.
AU - Degasperi, E.
AU - Puoti, M.
AU - Baiguera, C.
AU - D'AMICO, F.
AU - Vinci, M.
AU - Rumi, M.G.
AU - Zuin, M.
AU - Zermiani, P.
AU - Andreone, P.
AU - Caraceni, P.
AU - Guarneri, V.
AU - Villa, E.
AU - Bernabucci, V.
AU - Bristot, L.
AU - Paradiso, M.L.
AU - Migliorino, G.
AU - Gambaro, A.
AU - Lapadula, G.
AU - Spolti, A.
AU - Soria, A.
AU - Invernizzi, P.
AU - Ciaccio, A.
AU - LucÀ, M.
AU - Malinverno, F.
AU - Ratti, L.
AU - Amoruso, D.C.
AU - Pisano, F.
AU - Scarano, F.
AU - Staiano, L.
AU - Morisco, F.
AU - Cossiga, V.
AU - Gentile, I.
AU - Buonomo, A.R.
AU - Foggia, M.
AU - Zappulo, E.
AU - Federico, A.
AU - Dallio, M.
AU - Coppola, N.
AU - Sagnelli, C.
AU - Martini, S.
AU - Monari, C.
AU - Nardone, G.
AU - Sgamato, C.
AU - Chemello, L.
AU - Cavalletto, L.
AU - Sterrantino, D.
AU - Zanetto, A.
AU - Zanaga, P.
AU - Brancaccio, G.
AU - Craxì, A.
AU - Petta, S.
AU - Calvaruso, V.
AU - Crapanzano, L.
AU - Madonia, S.
AU - Cannizzaro, M.
AU - Bruno, E.M.
AU - Licata, A.
AU - Amodeo, S.
AU - Capitano, A.R.
AU - Ferrari, C.
AU - Negri, E.
AU - Orlandini, A.
AU - Pesci, M.
AU - Gulminetti, R.
AU - Pagnucco, L.
AU - Parruti, G.
AU - Stefano, P.D.
AU - Coco, B.
AU - Corsini, R.
AU - Garlassi, E.
AU - Andreoni, M.
AU - Teti, E.
AU - Cerva, C.
AU - Baiocchi, L.
AU - Grassi, G.
AU - Gasbarrini, A.
AU - Pompili, M.
AU - Siena, M.D.
AU - Taliani, G.
AU - Spaziante, M.
AU - Persico, M.
AU - Masarone, M.
AU - Aglitti, A.
AU - Calvanese, G.
AU - Anselmo, M.
AU - Leo, P.D.
AU - Marturano, M.
AU - Saracco, G.M.
AU - Group, PITER Collaborating
N1 - Export Date: 30 November 2021 CODEN: DLDIF Correspondence Address: Kondili, L.A.; Center for Global Health, Italy; email: loreta.kondili@iss.it Funding details: Ministero della Salute, 02364053, RF-2016 Funding text 1: This study was funded by Italian Ministry of Health, Grant number RF-2016?02364053. References: (2017), https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/2017, WHO global hepatitis report; Centers for Disease Control and Prevention, (2016), https://www.cdc.gov/hepatitis/statistics/2014surveillance/commentary.htm#summary, Surveillance for viral hepatitis – United States, 2014. 6 22; Gower, E., Estes, C., Blach, S., Global epidemiology and genotype distribution of the hepatitis C virus infection (2014) J Hepatol, 61, pp. S45-S57. , j; Messina, J.P., Humphreys, I., Flaxman, A., Global distribution and prevalence of hepatitis C virus genotypes (2015) Hepatology, 61, pp. 77-87; Benvegnù, L., Gios, M., Boccato, S., Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications (2004) Gut, 53, pp. 744-749; Lauer, G.M., Walker, B.D., Hepatitis C virus infection (2001) N Engl J Med, 345, pp. 41-52; European Centre for Disease Prevention and Control. Epidemiological Assessment of Hepatitis b and c Among Migrants in the EU/EEA (2016), ECDC Stockholm; Andriulli, A., Stroffolini, T., Mariano, A., Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas (2018) Eur J Intern Med, 53, pp. 79-84; Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection (2014) N Engl J Med, 370, pp. 211-221; Afdhal, N., Zeuzem, S., Kwo, P., Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection (2014) N Engl J Med, 370, pp. 1889-1898; Afdhal, N., Reddy, K.R., Nelson, D.R., Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection (2014) N Engl J Med, 370, pp. 1483-1493; European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series (2020) J Hepatol, 73, pp. 1170-1218; http://www.hcvguidelines.org, American Association for the Sudy of Liver Diseases, AASLD guidance: recommendations for Testing, Manging and Treating Hepatitis C; Kondili, L.A., Vella, S., PITER: an ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy (2015) Dig Liver Dis, 47, pp. 741-743; Ziol, M., Handra-Luca, A., Kettaneh, A., Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C (2005) Hepatology, 41, pp. 48-54; Dawson, D.A., Grant, B.F., Li, T.K., Quantifying the risks associated with exceeding recommended drinking limits (2005) Alcohol Clin Exp Res, 29, pp. 902-908; Guadagnino, V., Stroffolini, T., Rapicetta, M., Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy (1997) Hepatology, 26, pp. 1006-1011; Bellentani, S., Pozzato, G., Saccoccio, G., Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study (1999) Gut, 44, pp. 874-880; Moullan, Y., Jusot, F., Why is the 'healthy immigrant effect' different between European countries? (2014) Eur J Public Health, 24 (1), pp. 80-86. , SupplPMID: 25108002; https://www.dati.gov.it/dataset/lavoratori-domesticitipologia-rapporto-area-geografica-dati-trimestrali-2013-2014-4, INPS data. Available in; Cuomo, G., Franconi, I., Riva, N., Migration and health: a retrospective study about the prevalence of HBV, HIV, HCV, tuberculosis and syphilis infections amongst newly arrived migrants screened at the Infectious Diseases Unit of Modena, Italy (2019) J Infect Public Health, 12, pp. 200-204; Zanetti, A.R., Tanzi, E., Romano, L., Vaccination against hepatitis B: the Italian strategy (1993) Vaccine, 11, pp. 521-524; Bonanni, P., Implementation in Italy of a universal vaccination programme against hepatitis B (1995) Vaccine, 13 (1), pp. S68-S71. , Suppl; Stroffolini, T., The changing pattern of hepatitis B virus infection over the past three decades in Italy (2005) Dig Liver Dis, 37, pp. 622-627; Zanetti, A.R., Romano, L., Zappa, A., Changing patterns of hepatitis B infectionin Italy and NAT testing for improving the safety of blood supply (2006) J Clin Virol, 36 (1), pp. S51-S55. , Suppl; Zanetti, A.R., Van Damme, P., Shouval, D., The global impact of vaccination against hepatitis B: a historical overview (2008) Vaccine, 26, pp. 6266-6273
PY - 2021
Y1 - 2021
N2 - Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both groups, whereas genotype 4 was more prevalent in migrants (p < 0.05). Liver disease severity and sustained virologic response (SVR) were similar. A higher prevalence of comorbidities was reported for natives compared to migrants (p < 0.05). Liver disease progression cofactors (HBsAg, HIV coinfection, alcohol abuse, potential metabolic syndrome) were present in 39.1% and 47.1% (p > 0.05) of migrants and natives who eradicated HCV, respectively. Conclusion: Compared to natives, HCV-infected migrants in care have different demographics, HCV genotypes, viral coinfections and comorbidities and similar disease severity, SVR and cofactors for disease progression after HCV eradication. A periodic clinical assessment after HCV eradication in Italians and migrants with cofactors for disease progression is warranted. © 2021 The Authors
AB - Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both groups, whereas genotype 4 was more prevalent in migrants (p < 0.05). Liver disease severity and sustained virologic response (SVR) were similar. A higher prevalence of comorbidities was reported for natives compared to migrants (p < 0.05). Liver disease progression cofactors (HBsAg, HIV coinfection, alcohol abuse, potential metabolic syndrome) were present in 39.1% and 47.1% (p > 0.05) of migrants and natives who eradicated HCV, respectively. Conclusion: Compared to natives, HCV-infected migrants in care have different demographics, HCV genotypes, viral coinfections and comorbidities and similar disease severity, SVR and cofactors for disease progression after HCV eradication. A periodic clinical assessment after HCV eradication in Italians and migrants with cofactors for disease progression is warranted. © 2021 The Authors
KW - Comorbidities
KW - Direct acting antivirals
KW - HCV Cohort
KW - Linked-to-care patients
U2 - 10.1016/j.dld.2021.03.020
DO - 10.1016/j.dld.2021.03.020
M3 - Article
VL - 53
SP - 1603
EP - 1609
JO - Dig. Liver Dis.
JF - Dig. Liver Dis.
SN - 1590-8658
IS - 12
ER -